This recommendation came from evidence suggesting that IFN-ß reduced relapse risk in SPMS patients but was unable to significantly slow disability progression versus placebo (Panitch et al., 2004). This evidence concerns the gene IFNA1 and secondary progressive multiple sclerosis.